{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:56:50Z","timestamp":1775581010686,"version":"3.50.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The global prevalence of non-alcoholic fatty liver disease (NAFLD) has surged, largely driven by modern lifestyle changes and dietary shifts. As these factors profoundly impact human health, exploring effective therapeutic strategies for NAFLD has become a pressing medical concern. Previous studies have suggested that ginsenosides may offer a potential treatment approach for NAFLD by reducing oxidative stress and controlling inflammation. However, its efficacy and safety remain unclear. Therefore, the aim of this systematic review and meta-analysis is to evaluate the role of ginsenosides in the treatment of NAFLD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched for relevant studies published through September 2024, including databases such as PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang Data. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) Animal Experiment Bias Risk Assessment Tool was used to evaluate the quality of the literature. Subsequently, Review Manager (RevMan, version 5.3) and STATA 15 software was utilized for data analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Finally, 30 studies involving a total of 604 animals were included in the analysis. The results showed that, compared with the model group, ginsenosides significantly reduces total cholesterol (TC), triglycerides (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), low-density lipoprotein cholesterol (LDL), body weight, liver weight, liver index, serum insulin, tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1 (IL-1), interleukin-6 (IL-6) and NAFLD Activity Score (NAS). Due to the high heterogeneity, we conducted subgroup analyses of the main results ALT, AST, TC and TG by animal strains, modeling methods, administration methods, ginsenoside dosages and types of ginsenosides. The results showed that the heterogeneity of TC may be derived from differences in modeling methods. The results showed that the heterogeneity of TC may be derived from differences in modeling methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this study, we summarized the molecular mechanism of ginsenosides in regulating NAFLD, mainly focusing on inhibiting inflammation and oxidative stress, improving insulin sensitivity, and regulating intestinal flora. Preclinical evidence indicates that ginsenosides represent a novel therapeutic avenue for NAFLD. The mechanism of ginsenosides in treating NAFLD may involve anti-inflammation, antioxidation, improving insulin resistance, and regulating intestinal flora. However, the inclusion of studies with low methodological quality and the existence of publication bias may undermine the validity of the results. To fully elucidate the mechanisms underlying the therapeutic effects of ginsenosides, future research should employ more rigorous experimental designs and conduct comprehensive investigations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1564852","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:13:10Z","timestamp":1748319190000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Liyuan","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/s0006-2952(99)00212-9","article-title":"Ginseng pharmacology: multiple constituents and multiple actions","volume":"58","author":"Attele","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3390\/jcm8091385","article-title":"Relationship between oxidative stress, Er stress, and inflammation in type 2 diabetes: the battle continues","volume":"8","author":"Burgos-Mor\u00f3n","year":"2019","journal-title":"J. Clin. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.3390\/ijms21155214","article-title":"Gut microbiota metabolites in nafld pathogenesis and therapeutic implications","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fphar.2017.00636","article-title":"Food and sex-related impacts on the pharmacokinetics of a single-dose of ginsenoside compound K in healthy subjects","volume":"8","author":"Chen","year":"","journal-title":"Front. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"41144","DOI":"10.1038\/srep41144","article-title":"Ameliorative effects of compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats","volume":"7","author":"Chen","year":"","journal-title":"Sci. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (nafld) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug metab. Rev."},{"key":"B7","volume-title":"Research on the activation of sirt6 by ginsenoside rd to improve non-alcoholic fatty liver disease induced by high-fat diet","author":"Cui","year":"2024"},{"key":"B8","doi-asserted-by":"publisher","first-page":"29735","DOI":"10.1021\/acsomega.3c04122","article-title":"Harnessing the therapeutic potential of ginsenoside rd for activating Sirt6 in treating a mouse model of nonalcoholic fatty liver disease","volume":"8","author":"Cui","year":"2023","journal-title":"Acs Omega"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.3390\/ijms21113858","article-title":"Relevance of sirt1-nf-\u03bab Axis as therapeutic target to ameliorate inflammation in liver disease","volume":"21","author":"de Gregorio","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.13406\/j.cnki.cyxb.003212","article-title":"Effect of ginsenoside Rg1 on non-alcoholic fatty liver disease and intestinal microbiota in rats","volume":"48","author":"Gao","year":"2023","journal-title":"J. Chongqing Med. Univ."},{"key":"B11","doi-asserted-by":"publisher","first-page":"118986","DOI":"10.1016\/j.lfs.2020.118986","article-title":"Transcriptome analysis reveals the efficacy of ginsenoside-rg1 in the treatment of nonalcoholic fatty liver disease","volume":"267","author":"Gu","year":"2021","journal-title":"Life Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"9370","DOI":"10.1021\/acs.jafc.3c00789","article-title":"Ginsenoside Rk3 regulates nonalcoholic steatohepatitis by modulation of intestinal flora and the pi3k\/akt signaling pathway in C57bl\/6 mice","volume":"71","author":"Guo","year":"2023","journal-title":"J. Agric. Food Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"15489","DOI":"10.3390\/ijms232415489","article-title":"Non-alcoholic fatty liver disease (nafld) pathogenesis and natural products for prevention and treatment","volume":"23","author":"Guo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B14","first-page":"37","article-title":"Therapeutical effect of ginsenoside Rb1 on non-alcoholic fatty liver disease of mice","volume":"59","author":"Han","year":"2019","journal-title":"Shandong Med. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.13863\/j.issn1001-4454.2021.05.032","article-title":"Effect of ginsenoside Rg1 on liver fibrosis in mice with non-alcoholic fatty liver disease","volume":"44","author":"He","year":"2021","journal-title":"J. Chin. Med. Mater."},{"key":"B16","first-page":"338","article-title":"The effect and mechanism of ginsenoside rb2 on lipid metabolism in the liver of mice with hyperlipidemic fatty liver","volume":"48","author":"Hong","year":"2018","journal-title":"J. Wenzhou Med. Univ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"10878","DOI":"10.1021\/acsomega.0c00529","article-title":"Ginsenoside Rg1 regulates liver lipid factor metabolism in nafld model rats","volume":"5","author":"Hou","year":"2020","journal-title":"Acs Omega"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3390\/ijms18051063","article-title":"Ginsenoside Rb2 alleviates hepatic lipid accumulation by restoring autophagy via induction of Sirt1 and activation of ampk","volume":"18","author":"Huang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","article-title":"Immune cell-mediated features of non-alcoholic steatohepatitis","volume":"22","author":"Huby","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3904\/kjim.2015.208","article-title":"Compound K attenuates glucose intolerance and hepatic steatosis through ampk-dependent pathways in type 2 diabetic oletf rats","volume":"33","author":"Hwang","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"B21","volume-title":"Study on the molecular mechanism of ginsenoside rg1 regulating early liver fibrosis in non-alcoholic fatty liver disease","author":"Jiang","year":"2021"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9003603","DOI":"10.1155\/2021\/9003603","article-title":"Ginsenoside re improves inflammation and fibrosis in hepatic tissue by upregulating ppar\u03b3 expression and inhibiting oxidative stress in Db\/Db mice","volume":"2021","author":"Jiang","year":"2021","journal-title":"Evidence-based complementary Altern. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jgr.2017.12.003","article-title":"Micro-\/Nano-Sized delivery systems of ginsenosides for improved systemic bioavailability","volume":"42","author":"Kim","year":"2018","journal-title":"J. Ginseng Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1530\/joe-17-0233","article-title":"Ginsenoside Rg3 ameliorated hfd-induced hepatic steatosis through downregulation of stat5-ppar\u03b3","volume":"235","author":"Lee","year":"2017","journal-title":"J. Endocrinol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3390\/biom10101426","article-title":"Pharmaceutical efficacy of gypenoside lxxv on non-alcoholic steatohepatitis (nash)","volume":"10","author":"Lee","year":"2020","journal-title":"Biomolecules"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.4314\/tjpr.v23i8.2","article-title":"Ginsenoside R3 alleviates non-alcoholic fatty liver disease by regulating the PPAR\u03b3\/miR-103-3p pathway","volume":"23","author":"Li","year":"2024","journal-title":"Trop. J. Pharm. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1121821","DOI":"10.3389\/fphar.2022.1121821","article-title":"Editorial: recent advances in novel therapeutic molecules and targets for inflammatory diseases","volume":"13","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"155287","DOI":"10.1016\/j.phymed.2023.155287","article-title":"Ginsenoside Rg5 inhibits lipid accumulation and hepatocyte apoptosis via the Notch1 signaling pathway in nash mice","volume":"124","author":"Li","year":"2024","journal-title":"Phytomedicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"622841","DOI":"10.3389\/fphar.2021.622841","article-title":"Ginsenosides improve nonalcoholic fatty liver disease via integrated regulation of gut microbiota, inflammation and energy homeostasis","volume":"12","author":"Liang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B30","first-page":"2580","article-title":"Integrating network pharmacology and experimental verification to explore mechanism of ginsenoside Rb in treating metabolic associated fatty liver disease","volume":"46","author":"Liang","year":"2023","journal-title":"Drug Eval. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3969\/j.issn.1671-8348.2016.09.009","article-title":"Study on the improvement effect of ginsenoside rg1 on fatty acid \u03b2 -oxidation in rats with non-alcoholic fatty liver disease","volume":"45","author":"Liao","year":"2016","journal-title":"Chongqing Med. J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"109285","DOI":"10.1016\/j.cbi.2020.109285","article-title":"Anti-inflammatory and anti-gouty-arthritic effect of free ginsenoside Rb1 and nano ginsenoside Rb1 against msu induced gouty arthritis in experimental animals","volume":"332","author":"Liu","year":"2020","journal-title":"Chemico-biological Interact."},{"key":"B33","doi-asserted-by":"publisher","first-page":"110347","DOI":"10.1016\/j.biopha.2020.110347","article-title":"Hcbp6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice","volume":"129","author":"Lu","year":"2020","journal-title":"Biomed. and Pharmacother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2174\/157016109788340767","article-title":"Ginseng compounds: an update on their molecular mechanisms and medical applications","volume":"7","author":"L\u00fc","year":"2009","journal-title":"Curr. Vasc. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1039\/d3fo03572g","article-title":"Hepatoprotective efficacy and interventional mechanism of the panaxadiol saponin component in high-fat diet-induced nafld mice","volume":"15","author":"Mi","year":"2024","journal-title":"Food Funct."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.pharep.2019.07.004","article-title":"Ginsenoside Rg1 ameliorates palmitic acid-induced insulin resistance in Hepg2 cells in association with modulating akt and jnk activity","volume":"71","author":"Mo","year":"2019","journal-title":"Pharmacol. Rep. P. R."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"Nlrp3 inflammasome Blockade Reduces liver inflammation and fibrosis in experimental nash in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"B38","first-page":"864","article-title":"Ginsenoside Rg1 improves liver function by regulating fat metabolism in rats with non-alcoholic fatty liver disease","volume":"31","author":"Peng","year":"2015","journal-title":"Chin. J. Pathophysiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/nu14030716","article-title":"Simvastatin improves microcirculatory function in nonalcoholic fatty liver disease and downregulates oxidative and ale-rage stress","volume":"14","author":"Pereira","year":"2022","journal-title":"Nutrients"},{"key":"B40","doi-asserted-by":"publisher","first-page":"117776","DOI":"10.1016\/j.lfs.2020.117776","article-title":"Ginsenoside Rg1 protects against D-galactose induced fatty liver disease in a mouse model via Foxo1 transcriptional factor","volume":"254","author":"Qi","year":"2020","journal-title":"Life Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"112927","DOI":"10.1016\/j.jep.2020.112927","article-title":"Ginsenoside Mc1 improves liver steatosis and insulin resistance by attenuating Er stress","volume":"259","author":"Roh","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.13193\/j.issn.1673-7717.2020.08.025","article-title":"Research of mechanisms of ginsenosides adjusting glycolipid metabolism in nonalcoholic fatty liver disease rats","volume":"38","author":"Ruan","year":"2020","journal-title":"Chin. Archives Traditional Chin. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/nu16060842","article-title":"Ginsenoside rg(5) activates the lkb1\/ampk\/mtor signaling pathway and modifies the gut microbiota to alleviate nonalcoholic fatty liver disease induced by a high-fat diet","volume":"16","author":"Shi","year":"2024","journal-title":"Nutrients"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2315230","DOI":"10.1155\/2020\/2315230","article-title":"Ginsenoside Rb1 alleviated high-fat-diet-induced hepatocytic apoptosis via peroxisome proliferator-activated receptor \u0393","volume":"2020","author":"Song","year":"2020","journal-title":"Biomed Res. Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3969\/j.issn.1672-3619.2021.02.001","article-title":"Effect of ginsenoside Rb2 on nonalcoholic fatty liver disease in mice and its mechanism","volume":"21","author":"Wang","year":"2021","journal-title":"J. Trop. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"7514802","DOI":"10.1155\/2019\/7514802","article-title":"Ginsenoside Rg1 ameliorates palmitic acid-induced hepatic steatosis and inflammation in Hepg2 cells via the ampk\/nf-\u03bab pathway","volume":"2019","author":"Xiao","year":"","journal-title":"Int. J. Endocrinol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3969\/j.issn.2095-4344.0597","article-title":"Ginsenoside rg1 intervenes in the apoptosis of hepatocytes in rat models of non-alcoholic fatty liver disease","volume":"23","author":"Xiao","year":"","journal-title":"Chin. J. Tissue Eng. Res."},{"key":"B48","first-page":"3799","article-title":"The intervention effect of ginsenoside Rg1 on rats with non-alcoholic fatty liver disease","volume":"45","author":"Xie","year":"2023","journal-title":"Chin. Tradit. Pat. Med."},{"key":"B49","volume-title":"Study on the improvement effect and mechanism of ginsenoside Rg1 on non-alcoholic fatty liver disease in mice","author":"Xu","year":"2018"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1248\/bpb.b18-00132","article-title":"Ginsenoside Rg1 protects against non-alcoholic fatty liver disease by ameliorating lipid peroxidation, endoplasmic reticulum stress, and inflammasome activation","volume":"41","author":"Xu","year":"","journal-title":"Biol. and Pharm. Bull."},{"key":"B51","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3390\/nu15030721","article-title":"The efficacy of panax ginseng for the treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis of preclinical studies","volume":"15","author":"Yang","year":"","journal-title":"Nutrients"},{"key":"B52","doi-asserted-by":"publisher","first-page":"7653","DOI":"10.2147\/ijn.S144305","article-title":"Targeted delivery of ginsenoside compound K using tpgs\/peg-pcl mixed micelles for effective treatment of lung cancer","volume":"12","author":"Yang","year":"2017","journal-title":"Int. J. nanomedicine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.3390\/foods12132492","article-title":"Ginsenoside Rh4 improves hepatic lipid metabolism and inflammation in a model of nafld by targeting the gut liver Axis and modulating the fxr signaling pathway","volume":"12","author":"Yang","year":"","journal-title":"Foods"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3892\/mmr.2020.10935","article-title":"Ginsenosides reduce body weight and ameliorate hepatic steatosis in high fat diet-induced obese mice via endoplasmic reticulum stress and P-Stat3\/Stat3 signaling","volume":"21","author":"Yao","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"114292","DOI":"10.1016\/j.jep.2021.114292","article-title":"New mechanisms of ginseng saponin-mediated anti-inflammatory action via targeting canonical inflammasome signaling pathways","volume":"278","author":"Yi","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"116955","DOI":"10.1016\/j.biopha.2024.116955","article-title":"Comprehensive pharmacological and experimental study of ginsenoside re as a potential therapeutic agent for non-alcoholic fatty liver disease","volume":"177","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1039\/d1fo03026d","article-title":"Ginsenoside ck ameliorates hepatic lipid accumulation via activating the lkb1\/ampk pathway in vitro and in vivo","volume":"13","author":"Zhang","year":"2022","journal-title":"Food and Funct."},{"key":"B58","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jgr.2022.07.006","article-title":"Ginsenoside Rg1 ameliorates chronic intermittent hypoxia-induced vascular endothelial dysfunction by suppressing the formation of mitochondrial reactive oxygen species through the calpain-1 pathway","volume":"47","author":"Zhao","year":"2023","journal-title":"J. ginseng Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e2100296","DOI":"10.1002\/cbdv.202100296","article-title":"Biotransformation of ginsenosides (Rb(1), Rb(2), Rb(3), rc) in human intestinal bacteria and its effect on intestinal flora","volume":"18","author":"Zheng","year":"2021","journal-title":"Chem. and Biodivers."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1564852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:13:19Z","timestamp":1748319199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1564852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":59,"alternative-id":["10.3389\/fphar.2025.1564852"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1564852","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"article-number":"1564852"}}